Role of the complement system in NK cell-mediated antitumor T-cell responses

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Janelle, Valérie ^a,b   Lamarre, Alain ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Cancer; Complement; Immunotherapy; Melanoma; NK cells

Indexed keywords

ANGIOGENESIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; COMPLEMENT SYSTEM; DENDRITIC CELL; DOWN REGULATION; INNATE IMMUNITY; MELANOMA; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PHAGOCYTOSIS; T LYMPHOCYTE; TUMOR GROWTH;

EID: 84899099671     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27897     Document Type: Article

References (10)

1. Venkatesha RT, Berla Thangam E, Zaidi AK, Ali H. Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. Mol Immunol 2005; 42:581-7; PMID:15607817; http://dx.doi.org/10.1016/j. molimm.2004.09.009.
2. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40:109-23; PMID:12914817; http://dx.doi.org/10.1016/S0161-5890(03)00112-3.
3. Arase N, Arase H, Park SY, Ohno H, Ra C, Saito T. Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med 1997; 186:1957-63; PMID:9396764; http://dx.doi. org/10.1084/jem.186.12.1957.
4. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 2000; 97:2731-6; PMID:10694580; http://dx.doi.org/10.1073/pnas.050588297.
5. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106:566-71; PMID:15784725; http://dx.doi.org/10.1182/blood-2004-10-4035.
6. Janelle V, Langlois M-P, Tarrab E, Lapierre P, Poliquin L, Lamarre A. Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunology Research 2013.
7. Penafuerte C, Galipeau J. TGF β secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother 2008; 57:1197-206; PMID:18214474; http://dx.doi. org/10.1007/s00262-008-0453-1.
8. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD Jr., Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003; 101:611-20; PMID:12393562; http://dx.doi.org/10.1182/blood-2002-06-1769.
9. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116:2777-90; PMID:17016559; http://dx.doi.org/10.1172/JCI28828.
10. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9:1225-35; PMID:18820683; http://dx.doi. org/10.1038/ni.1655.